Overview A Phase 1b Study of ZN-c3 in Chinese Subjects Status: Recruiting Trial end date: 2023-06-30 Target enrollment: Participant gender: Summary This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN c3. Phase: Phase 1 Details Lead Sponsor: Zentera Therapeutics HK Limited